Cite

HARVARD Citation

    Simpson, E. et al. (2022). Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long‐term efficacy and patient‐reported outcomes. Dermatologic therapy. 35 (12), p. n/a. [Online]. 
  
Back to record